Showing results (241-250 of 793) with videos related to

Sort By:
Pageof 80
Blood Cancer Journal|December 4, 2025
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myelomaMeletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 28, 2026
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity ManagementRoberto Mina, Evangelos Terpos, Lorenzo Cani, et al.
Clinical Pharmacokinetics|November 30, 2016
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug TreatmentPamela L Clemens, Xiaoyu Yan, Henk M Lokhorst, et al.
American Heart Journal|June 23, 2009
Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial diseaseVeerappan Subramaniyam, Edmund K Waller, Jonathan R Murrow, et al.
Leukemia & Lymphoma|January 19, 2008
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosisMorie Gertz, Martha Lacy, Angela Dispenzieri, et al.
Blood Cancer Journal|February 16, 2023
Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significanceAlexander J Ryu, Shaji Kumar, Angela Dispenzieri, et al.
British Journal of Haematology|February 22, 2020
Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndromeTaxiarchis V Kourelis, Dragan Jevremovic, Erik Jessen, et al.
Blood Cancer Journal|August 30, 2019
Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapiesTaxiarchis V Kourelis, Jose C Villasboas, Erik Jessen, et al.
Research Square|February 27, 2026
Metabolic Heterogeneity and Niche Rewiring in Plasma Cells are Associated with Progression from MGUS to Multiple MyelomaAxel Walch, Guoxing Zhang, Na Sun, et al.
Blood|July 31, 2009
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2Mamta Gupta, Stephen M Ansell, Anne J Novak, et al.
Pageof 80